Latest Share Chat

ValiRx Share News (VAL)

ValiRx Information

Buy VAL Shares
Add VAL to Watchlist
Add VAL to Alert

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 3.60

Bid: 3.50

Ask: 3.70

Change: -0.40 (-10.00%)

Spread: 0.20 (5.714%)

Open: 4.15

High: 4.35

Low: 3.50

Prev. Close: 4.00

Last checked at -

ValiRx Confirms JV Talks For Non-Core Intellectual Property

Wed, 29th Apr 2020 18:19

(Alliance News) - Biotechnology company ValiRx PLC on Wednesday confirmed joint venture talks for its non-core intellectual property, GeneICE, TRAC and BioFit.

Shares in the company closed 25% higher at 7.49 pence each in London.

"The company confirms that it is in talks with a third-party in relation to a joint venture. However, there is no certainty the talks will conclude in a successful manner, nor that in the event that the Joint Venture is agreed, that the terms will be favourable to the company," ValiRx said in a statement.

By Tapan Panchal; tapanpanchal@alliancenews.com

More News

29 May 2020 15:02

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

29 May 2020 12:59

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

27 May 2020 14:20

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

7 May 2020 14:45

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

4 May 2020 16:18

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

4 May 2020 16:10

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

4 May 2020 14:26

ValiRx shores up capital position with ?1.17m fundraise

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced a conditional fundraise through the conditional issue of 18,069,467 new ordinary shares on Monday, to raise ?1.17m.

1 May 2020 14:57

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

1 May 2020 14:33

ValiRx signs VAL301 deal with Japanese firm

(Sharecast News) - Clinical-stage biotechnology company ValiRx has signed an agreement with an unnamed global Japanese pharmaceutical company to evaluate its therapeutic, VAL301, in order to contemplate a potential future license for its use in the treatment of endometriosis.

1 May 2020 14:23

Latest Share Chat

ValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

ValiRx Confirms JV Talks For Non-Core Intellectual Property

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

ValiRx offloads non-core IP to DDTech

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

ValiRx shores up capital position with ?1.17m fundraise

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

ValiRx signs VAL301 deal with Japanese firm

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

UK WINNERS & LOSERS SUMMARY: RBS Rises Despite Profit Sinking

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

UK Shareholder Meetings Calendar - Next 7 Days

ValiRx raises ?0.2m through placing with new investors

Latest Share Chat

ValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx Confirms JV Talks For Non-Core Intellectual Property

Login to your account

Quickpicks are a member only feature

Login to your account